DESTINY-Breast03 Phase 3 Study Results

Patient and Treatment Summary As of data cutoff, 30 patients enrolled in part A (dose escalation) had received DS-6000a (OVC, n=21; RCC, n=9) - 17 patients (56.7%) were receiving ongoing treatment with DS-6000a (OVC, n=12; RCC, n=5) - 13 patients (43.3%) discontinued treatment - 9 of 13 patients discontinued due to disease progression - 1 patient (3.3%) discontinued due to TEAE . Median treatment duration was 12.1 weeks (range, 3.0-54.1 weeks) Data cutoff: February 25, 2022. OVC, ovarian cancer; RCC, renal cell carcinoma; TEAE, treatment-emergent adverse event. ASCO 2022 #3002 Oral Daiichi-Sankyo 101

View entire presentation